

Q3FY2026 Results Preview

Sector:	Pharmaceuticals and Healthcare
Sector View:	Positive

Coverage universe

Company	CMP (Rs)	Reco	PT (Rs)
Torrent Pharmaceuticals Ltd.	3963	BUY	4273
Lupin Ltd.	2181	BUY	2400
Sun Pharmaceuticals Ltd.	1730	BUY	1968
IPCA Labs.	1570	BUY	1734
Divis Laboratories	6617	BUY	7375
Zydus Lifescience	895	BUY	1500
Dr. Reddy's Laboratories	1209	HOLD	1302
Aurobindo Pharma Ltd.	1199	HOLD	1663
Cipla Ltd.	1466	BUY	1726
Biocon Ltd.	380	BUY	462
Granules India Ltd.	602	BUY	700
Laurus Labs Ltd.	1082	HOLD	1054
Abbott India Ltd.	28043	BUY	34770

Source: Company, Mirae Asset Sharekhan Research estimates

*UR - Under Review

Summary

- Our universe of pharmaceutical companies is likely to clock~13% y-o-y revenue growth in Q2FY2026.
- Domestic market remains strong and our coverage universe is expected to outperform the IPM while price erosion in the US and lack of new product launches in the region will weigh down the performance of some of the export reliant companies.
- Overall EBITDA growth seen at 12% y-o-y with companies such as torrent, Laurus, Divis and Lupin to witness significant margin expansion.
- Sun Pharmaceuticals, Dr Reddy's to lag on account of gRevelimid impact and lack of significant launches in the near term.

Indian generics face a tempered outlook for Q3FY26 (October-December 2025), where challenges in the US market from pricing headwinds were largely counterbalanced by contributions from domestic sales and European expansion. Companies in our coverage are expected to see revenues grow by 13%, but strategic moves toward premium products in the exports and continued growth in the domestic market will help maintain EBITDA margins of 23-28% for most players, fostering resilience for leading companies.

◆ **Domestic companies to grow consistently:** The domestic branded generics segment continues to shine, (IPM projection of 9-11% through Q3FY26), building on strong performance in Q1. This momentum stems from fresh product introductions, modest price increases, and robust demand in chronic categories such as cardiology, despite subdued volume trends tied to seasonal patterns. Such dynamics affirm the home market's pivotal role in driving broader industry progress toward 9-11% for 2026. Torrent remains our top pick from this space with revenue growth of 20% and RBITDA growth expectation of 26% y-o-y.

◆ **Generics to drag on price erosion, complex drugs to shine:** In contrast to the IPM, the US generics arena anticipates subdued revenue growth in Q3FY26, hampered by significant revenue erosion from gRevelimid (impacting 10-15% of sales for key players) alongside fierce rivalry and sparse new ANDA (Abbreviated New Drug Application) clearances. On a brighter note, Europe counters these pressures with vigorous double-digit gains, propelled by biosimilar successes, competitive tenders, and steady pricing frameworks following Brexit-related changes, thereby bolstering export diversification. Lupin is likely to deliver strong 24.0% y-o-y revenue growth on account of launches, and traction in g-Tolvaptan/g-Spiriva/Mirabegron, offsetting price erosion in base portfolio and competition in g-Albuterol. Delayed competitor approval of g-Tolvaptan would extend the low-competition window, supporting continued growth.

◆ **Shift in sector, early companies to sustain higher valuations :** A transformative industry trend involves transitioning from basic generics to sophisticated offerings like biosimilars, peptide therapies, antibody-drug conjugates (ADCs), and GLP-1 agonists such as semaglutide variants. As per market reports, these advanced assets fetch 20-40% higher prices and deliver 30-35% margins—far surpassing the 15-20% from standard generics. Also CDMO companies are witnessing traction. Biocon, Laurus and Divis are standouts in this space.

Valuation:

We expect Q3FY26 numbers to be a mixed bag. For companies with a higher exposure to US, new launches into complex drugs/ biosimilars are key to margin growth. Companies have also used their US product pipeline to launch the same in Europe and have witnessed good traction. This has helped in diversifying the risk, while improving shareholder value.

Key risks: Larger-than-expected price erosion in the US, consolidation and growth in the diagnostics space taking longer than anticipated.

Leaders: Lupin Ltd, Torrent Pharmaceuticals, Divis Laboratories, Laurus Labs.

Laggards: Sun Pharmaceuticals, Dr Reddy's Laboratories.

Price chart



Source: NSE India, Mirae Asset Sharekhan Research

Q3FY26 Result estimates

Company	Revenue					EBITDA					PAT				
	Q3 FY26E	Q3 FY25	Y-o-Y (%)	Q2 FY26	Q-o-Q (%)	Q3 FY26E	Q3 FY25	Y-o-Y (%)	Q2 FY26	Q-o-Q (%)	Q3 FY26E	Q3 FY25	Y-o-Y (%)	Q2 FY26	Q-o-Q (%)
Torrent Pharmaceuticals Ltd.	3380.9	2809	20%	3246	4%	1148.6	914	26%	1083	6%	593.8	503	18%	591	0%
Lupin Ltd.	6979	5618.5	24%	6831.4	2%	1939.8	1365.8	42%	2137.6	-9%	1263.4	855.1	48%	1477.9	-15%
Sun Pharmaceuticals Ltd.	15530	13436.9	16%	14405.2	8%	4093	4192.3	-2%	4096.5	0%	3128	3124.7	0%	3117.9	0%
IPCA Labs.	2464	2245.3	10%	2556.5	-4%	576	463.08	24%	544.9	6%	281	248.1	13%	282.5	0%
Divis Laboratories	2811	2319	21%	2338	20%	961	743	29%	729	32%	691	589	17%	510	35%
Zydus Lifescience	6131	5237	17%	6123	0%	1524	1461.4	4%	1601.7	-5%	1002	910.9	10%	1258.6	-20%
Dr. Reddy's Laboratories	8364	8359	0%	8805	-5%	1809	2344	-23%	2323	-22%	1115	1413	-21%	1484	-25%
Aurobindo Pharma Ltd.	8486	7893.1	8%	8285.7	2%	1731	1627.8	6%	1678.1	3%	936	845.8	11%	848.4	10%
Cipla Ltd.	7109.1	6962	2%	7447	-5%	1697	1886	-10%	1895	-10%	1117	1303	-14%	1351	-17%
Biocon Ltd.	4566.2	4295.5	6%	3941.9	16%	871.4	835.4	4%	748.9	16%	164	25.1	553%	84.5	94%
Granules India Ltd.	1290.3	1137.7	13%	1296.9	-1%	279.1	230.3	21%	278.2	0%	140.3	117.6	19%	130.6	7%
Laurus Labs Ltd.	1415	1223.7	16%	1653.4	-14%	370.7	285.1	30%	403.2	-8%	168.9	92.3	83%	194.9	-13%
Abbott India Ltd.	1785.81	1614.2	11%	1757.1	2%	459	436	5%	502.1	-9%	372.3	360.7	3%	415.2	-10%
Total	5408.6	4857.7	13%	5283.7	2%	1343.0	1291.0	12%	1386.2	0%	843.9	799.1	57%	903.5	4%

Source: Company; Mirae Asset Sharekhan estimates

Valuations

Company	Reco.	Price Target (Rs.)	CMP (Rs.)	P/E (x)			EV/EBITDA (x)		
				FY25	FY26E	FY27E	FY25	FY26E	FY27E
Pharmaceuticals									
Torrent Pharmaceuticals Ltd.	3963	BUY	4273	56.2	54.5	42.7	30.7	31.8	26.2
Lupin Ltd.	2181	BUY	2400	28.0	21.5	20.8	18.0	14.6	13.7
Sun Pharmaceuticals Ltd.	1730	BUY	1968	37.3	35.9	35.1	25.1	23.4	21.7
IPCA Labs.	1570	BUY	1734	46.7	46.7	39.6	27	23	19
Divis Laboratories	6617	BUY	7375	71.5	63.2	53.5	45.6	41.2	34.8
Zydus Lifescience	895	BUY	1500	32.4	28	25.5	21	17.8	16.5
Dr. Reddy's Laboratories	1209	HOLD	1302	16.7	18.0	18.4	11.3	12.3	12.5
Aurobindo Pharma Ltd.	1199	HOLD	1663	22.6	22.6	-	9.7	9.7	-
Cipla Ltd.	1466	BUY	1726	22.2	26.3	23.8	16.3	18.0	16.3
Biocon Ltd.	380	BUY	462	42.6	82.0	58.9	17.0	18.9	14.9
Granules India Ltd.	602	BUY	700	26	21	28	14	12	10
Laurus Labs Ltd.	1082	HOLD	1054	87.4	69.2	50.2	23.59	14.77	12.23
Abbott India Ltd.	28043	BUY	34770	45.9	37.5	33.3	-	28.8	25.5

Source: Company; Mirae Asset Sharekhan estimates

Mirae Asset Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.

DISCLAIMER

This information/document has been prepared by Sharekhan Ltd. and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation, and any review, retransmission, or any other use is strictly prohibited. This information/ document is subject to change without prior notice.

Recommendation in reports based on technical and derivatives analysis is based on studying charts of a stock's price movement, trading volume, and outstanding positions, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals. However, this would only apply to information/documents focused on technical and derivatives research and shall not apply to reports/documents/information focused on fundamental research.

This information/document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. Mirae Asset Sharekhan will not treat recipients as customers by virtue of their receiving this information/report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable, and Mirae Asset Sharekhan has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on a reasonable basis, Mirae Asset Sharekhan, its subsidiaries and associated companies, their directors, and employees ("Mirae Asset Sharekhan and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent Mirae Asset Sharekhan and its affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance, and the value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Mirae Asset Sharekhan may have issued other recommendations/ reports that are inconsistent with and reach different conclusions from the information presented in this recommendations/report.

This information/recommendation/report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Mirae Asset Sharekhan and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restrictions.

The analyst certifies that the analyst might have dealt or traded directly or indirectly in the securities of the company and that all the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of Mirae Asset Sharekhan. The analyst and Mirae Asset Sharekhan further certifies that either he or his relatives or Mirae Asset Sharekhan associates might have direct or indirect financial interest or might have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report. The analyst and Mirae Asset Sharekhan encourage independence in research report/ material preparation and strive to minimize conflict in the preparation of the research report. The analyst and Mirae Asset Sharekhan do not have any material conflict of interest or have not served as officers, directors or employees or engaged in market-making activity of the company. The analyst and Mirae Asset Sharekhan have not been a part of the team which has managed or co-managed the public offerings of the company, and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Ltd, or its associates, or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from a third party in the past twelve months in connection with the research report.

Either Mirae Asset Sharekhan or its affiliates or its directors or employees/representatives/clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. Mirae Asset Sharekhan may from time to time solicit from, or perform investment banking or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall Mirae Asset Sharekhan, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Forward-looking statements (if any) are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not a guarantee of future performance, and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. Sharekhan Ltd and its affiliates undertake no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change, except as required by applicable securities laws. The reader/investors are cautioned not to place undue reliance on forward-looking statements and use their independent judgment before taking any investment decision.

Investment in securities market are subject to market risks, read all the related documents carefully before investing. The securities quoted are for illustration only and are not recommendatory. Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Mirae Asset Sharekhan has been ranked as India's No.1 Retail Broker by Asiamoney Brokers Poll 2023. For more details, visit bit.ly/AsiamoneyPoll

Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on www.sharekhan.com

Registered Office: 1st Floor, Tower No. 3, Equinox Business Park, LBS Marg, Off BKC, Kurla (West), Mumbai 400 070, Maharashtra, India. Tel: 022-67502000.

Correspondence/Administrative Office Address - Gigaplex IT Park, Unit No 1001, 10th floor, Building No.9, TTC Industrial Area, Digha, Airoli-West, Navi Mumbai - 400708. Tel: 022 61169000 / 61150000, Fax No. 61169699.

Registration and Contact Details: Name of Research Analyst - Sharekhan Limited - (AMFI-registered Mutual Fund Distributor), Research Analyst Regn No.: INH000006183. CIN: U99999MH1995PLC087498.

SEBI Regn. Nos.: BSE / NSE (CASH / F&O / CD) / MCX - Commodity: INZ000171337; BSE - 748, NSE - 10733, MCX - 56125, DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669 (date of initial registration: 03/07/2004, and valid till 02/07/2026); IRDAI Registered Corporate Agent (Composite) License No. CA0950, valid till June 13, 2027.

Compliance Officer: Mr. Joby John Meledan; Tel: 022-4657 3809; email id: complianceofficer@sharekhan.com

For any complaints/ grievances, email us at igc@sharekhan.com, or you may even call the Customer Service desk on 022-41523200/ 022-61151111.